{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:57:08Z","timestamp":1756810628557,"version":"3.37.3"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Key R&D Program","award":["2017YFD0200501"],"award-info":[{"award-number":["2017YFD0200501"]}]},{"DOI":"10.13039\/501100002858","name":"The China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2020M672390"],"award-info":[{"award-number":["2020M672390"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key Research and Development Program of Hubei Province, China","award":["2020BCB042"],"award-info":[{"award-number":["2020BCB042"]}]},{"name":"the Science and Technology Program of Wuhan","award":["2019020701011460"],"award-info":[{"award-number":["2019020701011460"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Top Curr Chem (Z)"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Coronavirus disease 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still a pandemic around the world. Currently, specific antiviral drugs to control the epidemic remain deficient. Understanding the details of SARS-CoV-2 structural biology is extremely important for development of antiviral agents that will enable regulation of its life cycle. This review focuses on the structural biology and medicinal chemistry of various key proteins (Spike, ACE2, TMPRSS2, RdRp and M<jats:sup>pro<\/jats:sup>) in the life cycle of SARS-CoV-2, as well as their inhibitors\/drug candidates. Representative broad-spectrum antiviral drugs, especially those against the homologous virus SARS-CoV, are summarized with the expectation they will drive the development of effective, broad-spectrum inhibitors against coronaviruses. We are hopeful that this review will be a useful aid for discovery of novel, potent anti-SARS-CoV-2 drugs with excellent therapeutic results in the near future.<\/jats:p>","DOI":"10.1007\/s41061-021-00335-9","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T15:04:54Z","timestamp":1619103894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology"],"prefix":"10.1007","volume":"379","author":[{"given":"Lin-Sheng","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Chuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Qing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4384-2593","authenticated-orcid":false,"given":"Guang-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"335_CR1","unstructured":"https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"335_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"key":"335_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.1103.1102.972927","author":"C Liu","year":"2020","unstructured":"Liu C, Yang Y, Gao YZ, Shen CG, Ju B, Liu CC, Tang X, Wei JL, Ma XM, Liu WL, Xu SM, Liu YX, Yuan J, Wu J, Liu Z, Zhang Z, Wang PY, Liu L (2020) Viral architecture of SARS-CoV-2 with post-fusion spike revealed by cryo-EM. BioRxiv. https:\/\/doi.org\/10.1101\/2020.1103.1102.972927","journal-title":"BioRxiv"},{"key":"335_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281\u2013292","journal-title":"Cell"},{"key":"335_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/pathogens9030231","volume":"9","author":"FA Rabi","year":"2020","unstructured":"Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD (2020) SARS-CoV-2 and coronavirus disease 2019: what we know so far. Pathogens 9:231","journal-title":"Pathogens"},{"key":"335_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.cell.2020.04.013","volume":"181","author":"B Oberfeld","year":"2020","unstructured":"Oberfeld B, Achanta A, Carpenter K, Chen P, Gilette NM, Langat P, Said JT, Schiff AE, Zhou AS, Barczak AK, Pillai S (2020) SnapShot: COVID-19. Cell 181:954\u2013954","journal-title":"Cell"},{"key":"335_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","volume":"66","author":"PS Masters","year":"2006","unstructured":"Masters PS (2006) The molecular biology of coronaviruses. Adv Virus Res 66:193\u2013292","journal-title":"Adv Virus Res"},{"key":"335_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jmv.25681","volume":"92","author":"Y Chen","year":"2020","unstructured":"Chen Y, Liu Q, Guo D (2020) Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418\u2013423","journal-title":"J Med Virol"},{"key":"335_CR9","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"QH Wang","year":"2020","unstructured":"Wang QH, Zhang YF, Wu LL, Niu S, Song CL, Zhang ZY, Lu GW, Qiao CP, Hu Y, Yuen KY, Wang QS, Zhou H, Yan JH, Qi JX (2020) Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181:894\u2013904","journal-title":"Cell"},{"key":"335_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","volume":"105","author":"MA Tortorici","year":"2019","unstructured":"Tortorici MA, Veesler D (2019) Structural insights into coronavirus entry. Adv Virus Res 105:93\u2013116","journal-title":"Adv Virus Res"},{"key":"335_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41594-019-0233-y","volume":"26","author":"MA Tortorici","year":"2019","unstructured":"Tortorici MA, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, Boons GJ, Bosch BJ, Rey FA, de Groot RJ, Veesler D (2019) Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol 26:481\u2013489","journal-title":"Nat Struct Mol Biol"},{"key":"335_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450\u2013454","journal-title":"Nature"},{"key":"335_CR13","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1126\/science.1116480","volume":"309","author":"F Li","year":"2005","unstructured":"Li F, Li WH, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864\u20131868","journal-title":"Science"},{"key":"335_CR14","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/sj.emboj.7600640","volume":"24","author":"WH Li","year":"2005","unstructured":"Li WH, Zhang CS, Sui JH, Kuhn JH, Moore MJ, Luo SW, Wong SK, Huang IC, Xu KM, Vasilieva N, Murakami A, He YQ, Marasco WA, Guan Y, Choe HY, Farzan M (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24:1634\u20131643","journal-title":"EMBO J"},{"key":"335_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang NS, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260\u20131263","journal-title":"Science"},{"key":"335_CR16","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","volume":"77","author":"BJ Bosch","year":"2003","unstructured":"Bosch BJ, van der Zee R, de Haan CAM, Rottier PJM (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77:8801\u20138811","journal-title":"J Virol"},{"key":"335_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","volume":"3","author":"F Li","year":"2016","unstructured":"Li F (2016) Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 3:237\u2013261","journal-title":"Annu Rev Virol"},{"key":"335_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Krueger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Mueller MA, Drosten C, Poehlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271\u2013280","journal-title":"Cell"},{"key":"335_CR19","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.abc5881","volume":"369","author":"Z Lv","year":"2020","unstructured":"Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li XF, Li Q, Xie L, Wang Y, Rao Z, Qin CF, Wang X (2020) Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369:1505\u20131509","journal-title":"Science"},{"key":"335_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30:343\u2013355","journal-title":"Cell Res"},{"key":"335_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369:77\u201381","journal-title":"Science"},{"key":"335_CR22","doi-asserted-by":"publisher","first-page":"8887","DOI":"10.1128\/JVI.00415-08","volume":"82","author":"BJ Bosch","year":"2008","unstructured":"Bosch BJ, Bartelink W, Rottier PJM (2008) Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J Virol 82:8887\u20138890","journal-title":"J Virol"},{"key":"335_CR23","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1073\/pnas.0809524106","volume":"106","author":"S Belouzard","year":"2009","unstructured":"Belouzard S, Chu VC, Whittaker GR (2009) Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A 106:5871\u20135876","journal-title":"Proc Natl Acad Sci U S A"},{"key":"335_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41594-020-0468-7","volume":"27","author":"AG Wrobel","year":"2020","unstructured":"Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ (2020) SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat Struct Mol Biol 27:763\u2013767","journal-title":"Nat Struct Mol Biol"},{"key":"335_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/2020.1102.1111.20022228","author":"C Wu","year":"2020","unstructured":"Wu C, Zheng S, Chen Y, Zheng M (2020) Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue. medRxiv. https:\/\/doi.org\/10.1101\/2020.1102.1111.20022228","journal-title":"medRxiv"},{"key":"335_CR26","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","volume":"87","author":"M Donoghue","year":"2000","unstructured":"Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139. Circ Res 87:E1\u2013E9","journal-title":"Circ Res"},{"key":"335_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/2020.1101.1130.927806","author":"H Zhang","year":"2020","unstructured":"Zhang H, Kang ZJ, Gong HY, Xu D, Wang J, Li ZF, Cui XG, Xiao JR, Meng T, Zhou W, Liu JM, Xu HJ (2020) The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. https:\/\/doi.org\/10.1101\/2020.1101.1130.927806","journal-title":"bioRxiv"},{"key":"335_CR28","doi-asserted-by":"publisher","first-page":"17132","DOI":"10.1074\/jbc.M006723200","volume":"276","author":"H Zhang","year":"2001","unstructured":"Zhang H, Wada J, Hida K, Tsuchiyama Y, Hiragushi K, Shikata K, Wang H, Lin S, Kanwar YS, Makino H (2001) Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 276:17132\u201317139","journal-title":"J Biol Chem"},{"key":"335_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","volume":"9","author":"XL Tian","year":"2020","unstructured":"Tian XL, Li C, Huang AL, Xia S, Lu SC, Shi ZL, Lu L, Jiang SB, Yang ZL, Wu YL, Ying TL (2020) Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microb Infect 9:382\u2013385","journal-title":"Emerg Microb Infect"},{"key":"335_CR30","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1096\/fj.08-107300","volume":"22","author":"S Kowalczuk","year":"2008","unstructured":"Kowalczuk S, Br\u00f6er A, Tietze N, Vanslambrouck JM, Rasko JEJ, Br\u00f6er S (2008) A protein complex in the brush-border membrane explains a Hartnup disorder allele. FASEB J 22:2880\u20132887","journal-title":"FASEB J"},{"key":"335_CR31","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444\u20131448","journal-title":"Science"},{"key":"335_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge JW, Yu JF, Shan SS, Zhou H, Fan SL, Zhang Q, Shi XL, Wang QS, Zhang LQ, Wang XQ (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581:215\u2013220","journal-title":"Nature"},{"key":"335_CR33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F (2020) Structural basis of receptor recognition by SARS-CoV-2. Nature 581:221\u2013224","journal-title":"Nature"},{"key":"335_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","volume":"116","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Poehlmann S, McKerrow JH, Renslo AR, Simmons G (2015) Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116:76\u201384","journal-title":"Antiviral Res"},{"key":"335_CR35","doi-asserted-by":"publisher","first-page":"e38567","DOI":"10.1371\/journal.pone.0035876","volume":"7","author":"S Bertram","year":"2012","unstructured":"Bertram S, Heurich A, Lavender H, Gierer S, Danisch S, Perin P, Lucas JM, Nelson PS, Poehlmann S, Soilleux EJ (2012) Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS ONE 7:e38567","journal-title":"PLoS ONE"},{"key":"335_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acschemneuro.0c00210","volume":"11","author":"K Bilinska","year":"2020","unstructured":"Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R (2020) Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem Neurosci 11:1555\u20131562","journal-title":"ACS Chem Neurosci"},{"key":"335_CR37","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00705-007-0974-5","volume":"152","author":"L Shi","year":"2007","unstructured":"Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z (2007) Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 152:1447\u20131455","journal-title":"Arch Virol"},{"key":"335_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00705-009-0346-4","volume":"154","author":"Q Zhong","year":"2009","unstructured":"Zhong Q, Yang Z, Liu Y, Deng H, Xiao H, Shi L, He J (2009) Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol 154:601\u2013607","journal-title":"Arch Virol"},{"key":"335_CR39","doi-asserted-by":"publisher","first-page":"e15874","DOI":"10.1371\/journal.pone.0015874","volume":"6","author":"E Teissier","year":"2011","unstructured":"Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Boeckmann A, Meier BH, Penin F, Pecheur EI (2011) Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS ONE 6:e15874","journal-title":"PLoS ONE"},{"key":"335_CR40","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/JVI.00094-12","volume":"86","author":"M Kawase","year":"2012","unstructured":"Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S (2012) Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 86:6537\u20136545","journal-title":"J Virol"},{"key":"335_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0301-0503(84)80235-0","volume":"12","author":"M Ohkoshi","year":"1984","unstructured":"Ohkoshi M, Oka T (1984) Clinical experience with a protease inhibitor N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma. J Maxillofac Surg 12:148\u2013152","journal-title":"J Maxillofac Surg"},{"key":"335_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00535-009-0148-1","volume":"45","author":"JK Sai","year":"2010","unstructured":"Sai JK, Suyama M, Kubokawa Y, Matsumura Y, Inami K, Watanabe S (2010) Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease. J Gastroenterol 45:335\u2013341","journal-title":"J Gastroenterol"},{"key":"335_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/039139888801100316","volume":"11","author":"M Hiraishi","year":"1988","unstructured":"Hiraishi M, Yamazaki Z, Ichikawa K, Kanai F, Idezuki Y, Onishi K, Takahama T, Inoue N (1988) Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant. Int J Artif Organs 11:212\u2013216","journal-title":"Int J Artif Organs"},{"key":"335_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00535-019-01644-z","volume":"55","author":"M Hirota","year":"2020","unstructured":"Hirota M, Shimosegawa T, Kitamura K, Takeda K, Takeyama Y, Mayumi T, Ito T, Takenaka M, Iwasaki E, Sawano H, Ishida E, Miura S, Masamune A, Nakai Y, Mitoro A, Maguchi H, Kimura K, Sanuki T, Ito T, Haradome H, Kozaka K, Gabata T, Kataoka K, Hirota M, Isaji S, Nakamura R, Yamagiwa K, Kayaba C, Ikeda K (2020) Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial. J Gastroenterol 55:342\u2013352","journal-title":"J Gastroenterol"},{"key":"335_CR45","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","volume":"60","author":"M Yamamoto","year":"2016","unstructured":"Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue J-i, Matsuda Z (2016) Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother 60:6532\u20136539","journal-title":"Antimicrob Agents Chemother"},{"key":"335_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269\u2013271","journal-title":"Cell Res"},{"key":"335_CR47","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.4049\/jimmunol.1303276","volume":"193","author":"A Said","year":"2014","unstructured":"Said A, Bock S, Lajqi T, Mueller G, Weindl G (2014) Chloroquine promotes IL-17 production by CD4(+) T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol 193:6135\u20136143","journal-title":"J Immunol"},{"key":"335_CR48","doi-asserted-by":"publisher","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","volume":"55","author":"P Colson","year":"2020","unstructured":"Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D (2020) Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 55:105932","journal-title":"Int J Antimicrob Agents"},{"key":"335_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","volume":"14","author":"J Gao","year":"2020","unstructured":"Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72\u201373","journal-title":"Biosci Trends"},{"key":"335_CR50","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1473-3099(20)30296-6","volume":"20","author":"N Principi","year":"2020","unstructured":"Principi N, Esposito S (2020) Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis 20:1118\u20131118","journal-title":"Lancet Infect Dis"},{"key":"335_CR51","doi-asserted-by":"publisher","first-page":"e1003252","DOI":"10.1371\/journal.pmed.1003252","volume":"17","author":"NJ White","year":"2020","unstructured":"White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J (2020) COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Med 17:e1003252","journal-title":"PLoS Med"},{"key":"335_CR52","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamainternmed.2020.1853","volume":"180","author":"C DeJong","year":"2020","unstructured":"DeJong C, Wachter RM (2020) The risks of prescribing hydroxychloroquine for treatment of COVID-19\u2014first, do no harm. JAMA Intern Med 180:1118","journal-title":"JAMA Intern Med"},{"key":"335_CR53","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","volume":"75","author":"A Gerard","year":"2020","unstructured":"Gerard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, Chouchana L, Rocher F, Drici M-D, French Network Pharmacovigilance C (2020) \u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie 75:371\u2013379","journal-title":"Therapie"},{"key":"335_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/jmv.25761","volume":"92","author":"J Lung","year":"2020","unstructured":"Lung J, Lin YS, Yang YH, Chou YL, Shu LH, Cheng YC, Liu HT, Wu CY (2020) The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol 92:693\u2013697","journal-title":"J Med Virol"},{"key":"335_CR55","doi-asserted-by":"publisher","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","volume":"178","author":"A Shannon","year":"2020","unstructured":"Shannon A, Le NTT, Selisko B, Eydoux C, Alvarez K, Guillemot JC, Decroly E, Peersen O, Ferron F, Canard B (2020) Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antiviral Res 178:104793\u2013104793","journal-title":"Antiviral Res"},{"key":"335_CR56","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.abb7498","volume":"368","author":"Y Gao","year":"2020","unstructured":"Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, Sun Q, Ming Z, Zhang L, Ge J, Zheng L, Zhang Y, Wang H, Zhu Y, Zhu C, Hu T, Hua T, Zhang B, Yang X, Li J, Yang H, Liu Z, Xu W, Guddat LW, Wang Q, Lou Z, Rao Z (2020) Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368:779\u2013782","journal-title":"Science"},{"key":"335_CR57","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"WC Yin","year":"2020","unstructured":"Yin WC, Mao CY, Luan XD, Shen DD, Shen QY, Su HX, Wang XX, Zhou FL, Zhao WF, Gao MQ, Chang SH, Xie YC, Tian GH, Jiang HW, Tao SC, Shen JS, Jiang Y, Jiang HL, Xu YC, Zhang SY, Zhang Y, Xu HE (2020) Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368:1499\u20131504","journal-title":"Science"},{"key":"335_CR58","doi-asserted-by":"publisher","first-page":"107774","DOI":"10.1016\/j.celrep.2020.107774","volume":"31","author":"Q Peng","year":"2020","unstructured":"Peng Q, Peng R, Yuan B, Zhao J, Wang M, Wang X, Wang Q, Sun Y, Fan Z, Qi J, Gao GF, Shi Y (2020) Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2. Cell Rep 31:107774","journal-title":"Cell Rep"},{"key":"335_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P (2020) Structure of replicating SARS-CoV-2 polymerase. Nature 584:154\u2013156","journal-title":"Nature"},{"key":"335_CR60","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1038\/s41467-020-19770-1","volume":"11","author":"L Yan","year":"2020","unstructured":"Yan L, Zhang Y, Ge J, Zheng L, Gao Y, Wang T, Jia Z, Wang H, Huang Y, Li M, Wang Q, Rao Z, Lou Z (2020) Architecture of a SARS-CoV-2 mini replication and transcription complex. Nat Commun 11:5874","journal-title":"Nat Commun"},{"key":"335_CR61","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","volume":"53","author":"SS Jean","year":"2020","unstructured":"Jean SS, Lee PI, Hsueh PR (2020) Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect 53:436\u2013443","journal-title":"J Microbiol Immunol Infect"},{"key":"335_CR62","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:149\u2013150","journal-title":"Nat Rev Drug Discov"},{"key":"335_CR63","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9:e00221-e218","journal-title":"MBio"},{"key":"335_CR64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature13027","volume":"508","author":"TK Warren","year":"2014","unstructured":"Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S (2014) Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508:402\u2013405","journal-title":"Nature"},{"key":"335_CR65","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3109\/08923973.2014.971962","volume":"36","author":"D Savic","year":"2014","unstructured":"Savic D, Stojiljkovic M, Lavrnja I, Parabucki A, Bjelobaba I, Nedeljkovic N, Herdegen T, Pekovic S (2014) Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacol Immunotoxicol 36:433\u2013441","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"335_CR66","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","volume":"212","author":"JFW Chan","year":"2015","unstructured":"Chan JFW, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY (2015) Treatment with lopinavir\/ritonavir or interferon-beta 1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904\u20131913","journal-title":"J Infect Dis"},{"key":"335_CR67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13104-015-1253-2","volume":"8","author":"B Refaat","year":"2015","unstructured":"Refaat B, El-Shemi AG, Ashshi AM (2015) The effects of pegylated interferon-\u03b1 and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Res Notes 8:265","journal-title":"BMC Res Notes"},{"key":"335_CR68","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.7314\/APJCP.2016.17.4.1979","volume":"17","author":"NM Abdel-Hamid","year":"2016","unstructured":"Abdel-Hamid NM, Wahid A, Nazmy MH, Eisa MAM (2016) Synergistic effects of Jerusalem artichoke in combination with pegylated interferon Alfa-2a and ribavirin against hepatic fibrosis in rats. Asian Pac J Cancer Prev 17:1979\u20131985","journal-title":"Asian Pac J Cancer Prev"},{"key":"335_CR69","doi-asserted-by":"publisher","first-page":"eaax5866","DOI":"10.1126\/scitranslmed.aax5866","volume":"11","author":"M Toots","year":"2019","unstructured":"Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK (2019) Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med 11:eaax5866","journal-title":"Sci Transl Med"},{"key":"335_CR70","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1126\/scitranslmed.abb5883","volume":"12","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH III, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 12:5883","journal-title":"Sci Transl Med"},{"key":"335_CR71","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446\u2013454","journal-title":"Antiviral Res"},{"key":"335_CR72","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","volume":"424","author":"J Rocha-Pereira","year":"2012","unstructured":"Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MSJ, Neyts J (2012) Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 424:777\u2013780","journal-title":"Biochem Biophys Res Commun"},{"key":"335_CR73","unstructured":"https:\/\/www.shine.cn\/news\/nation\/2003174503\/"},{"key":"335_CR74","doi-asserted-by":"publisher","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","volume":"285","author":"E Murakami","year":"2010","unstructured":"Murakami E, Tolstykh T, Bao H, Niu C, Steuer HMM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA (2010) Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285:34337\u201334347","journal-title":"J Biol Chem"},{"key":"335_CR75","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1038\/s41598-017-06612-2","volume":"7","author":"HT Xu","year":"2017","unstructured":"Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA (2017) Evaluation of sofosbuvir (beta-D-2\u2019-deoxy-2\u2019-alpha-fluoro-2\u2019-beta-C-methyluridine) as an inhibitor of Dengue virus replication. Sci Rep 7:6345","journal-title":"Sci Rep"},{"key":"335_CR76","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"AA Elfiky","year":"2020","unstructured":"Elfiky AA (2020) Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci 253:117592\u2013117592","journal-title":"Life Sci"},{"key":"335_CR77","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","volume":"27","author":"A Wu","year":"2020","unstructured":"Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T (2020) Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27:325\u2013328","journal-title":"Cell Host Microbe"},{"key":"335_CR78","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1148\/radiol.2020200274","volume":"295","author":"F Song","year":"2020","unstructured":"Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, Ling Y, Jiang Y, Shi Y (2020) Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 295:210\u2013217","journal-title":"Radiology"},{"key":"335_CR79","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003) Coronavirus main proteinase (3CL(pro)) structure: basis for design of anti-SARS drugs. Science 300:1763\u20131767","journal-title":"Science"},{"key":"335_CR80","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1111\/febs.12936","volume":"281","author":"R Hilgenfeld","year":"2014","unstructured":"Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281:4085\u20134096","journal-title":"FEBS J"},{"key":"335_CR81","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"T Pillaiyar","year":"2016","unstructured":"Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH (2016) An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 59:6595\u20136628","journal-title":"J Med Chem"},{"key":"335_CR82","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"ZM Jin","year":"2020","unstructured":"Jin ZM, Du XY, Xu YC, Deng YQ, Liu MQ, Zhao Y, Zhang B, Li XF, Zhang LK, Peng C, Duan YK, Yu J, Wang L, Yang KL, Liu FJ, Jiang RD, Yang XL, You T, Liu X, Yang XN, Bai F, Liu H, Liu X, Guddat LW, Xu WQ, Xiao GF, Qin CF, Shi ZL, Jiang HL, Rao ZH, Yang HT (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293","journal-title":"Nature"},{"key":"335_CR83","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1073\/pnas.0510851103","volume":"103","author":"K Ratia","year":"2006","unstructured":"Ratia K, Saikatendu KS, Santarsiero BD, Barretto N, Baker SC, Stevens RC, Mesecar AD (2006) Severe acute respiratory syndrome coronavirus papain-like protease: tructure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA 103:5717\u20135722","journal-title":"Proc Natl Acad Sci USA"},{"key":"335_CR84","doi-asserted-by":"publisher","first-page":"10063","DOI":"10.1128\/JVI.00898-10","volume":"84","author":"JA Wojdyla","year":"2010","unstructured":"Wojdyla JA, Manolaridis I, van Kasteren PB, Kikkert M, Snijder EJ, Gorbalenya AE, Tucker PA (2010) Papain-like protease 1 from transmissible gastroenteritis virus: crystal structure and enzymatic activity toward viral and cellular substrates. J Virol 84:10063\u201310073","journal-title":"J Virol"},{"key":"335_CR85","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1107\/S1399004715003521","volume":"71","author":"D Needle","year":"2015","unstructured":"Needle D, Lountos GT, Waugh DS (2015) Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Crystallogr Sect D Struct Biol 71:1102\u20131111","journal-title":"Acta Crystallogr Sect D Struct Biol"},{"key":"335_CR86","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.1016\/j.bmc.2015.06.039","volume":"23","author":"SE St John","year":"2015","unstructured":"St John SE, Tomar S, Stauffer SR, Mesecar AD (2015) Targeting zoonotic viruses: structure-based inhibition of the 3C-like protease from bat coronavirus HKU4-The likely reservoir host to the human coronavirus that causes Middle East respiratory syndrome (MERS). Biorg Med Chem 23:6036\u20136048","journal-title":"Biorg Med Chem"},{"key":"335_CR87","doi-asserted-by":"publisher","first-page":"19403","DOI":"10.1074\/jbc.M115.651463","volume":"290","author":"S Tomar","year":"2015","unstructured":"Tomar S, Johnston ML, John SES, Osswald HL, Nyalapatla PR, Paul LN, Ghosh AK, Denison MR, Mesecar AD (2015) Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implications for nsp5 regulation and the development of antivirals. J Biol Chem 290:19403\u201319422","journal-title":"J Biol Chem"},{"key":"335_CR88","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1021\/acscatal.0c00110","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang H, He S, Deng W, Zhang Y, Li G, Sun J, Zhao W, Guo Y, Yin Z, Li D, Shang L (2020) Comprehensive insights into the catalytic mechanism of Middle East respiratory syndrome 3C-like protease and severe acute respiratory syndrome 3C-like protease. ACS Catal 10:5871\u20135890","journal-title":"ACS Catal"},{"key":"335_CR89","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 368:409\u2013412","journal-title":"Science"},{"key":"335_CR90","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1021\/jm060207o","volume":"49","author":"IL Lu","year":"2006","unstructured":"Lu IL, Mahindroo N, Liang PH, Peng YH, Kuo CJ, Tsai KC, Hsieh HP, Chao YS, Wu SY (2006) Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem 49:5154\u20135161","journal-title":"J Med Chem"},{"key":"335_CR91","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","volume":"21","author":"K Anand","year":"2002","unstructured":"Anand K, Palm GJ, Mesters JR, Siddell SG, Ziebuhr J, Hilgenfeld R (2002) Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra \u03b1-helical domain. EMBO J 21:3213\u20133224","journal-title":"EMBO J"},{"key":"335_CR92","doi-asserted-by":"publisher","first-page":"13190","DOI":"10.1073\/pnas.1835675100","volume":"100","author":"H Yang","year":"2003","unstructured":"Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, Sun L, Mo L, Ye S, Pang H, Gao GF, Anand K, Bartlam M, Hilgenfeld R, Rao Z (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci 100:13190\u201313195","journal-title":"Proc Natl Acad Sci"},{"key":"335_CR93","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/JVI.02114-07","volume":"82","author":"X Xue","year":"2008","unstructured":"Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W, Li J, Zhou Z, Ding Y, Zhao Q, Zhang XC, Liao M, Bartlam M, Rao Z (2008) Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol 82:2515\u20132527","journal-title":"J Virol"},{"key":"335_CR94","doi-asserted-by":"publisher","first-page":"22677","DOI":"10.1038\/srep22677","volume":"6","author":"F Wang","year":"2016","unstructured":"Wang F, Chen C, Tan W, Yang K, Yang H (2016) Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci Rep 6:22677","journal-title":"Sci Rep"},{"key":"335_CR95","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jmb.2005.09.012","volume":"354","author":"J Tan","year":"2005","unstructured":"Tan J, Verschueren KHG, Anand K, Shen J, Yang M, Xu Y, Rao Z, Bigalke J, Heisen B, Mesters JR (2005) pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol. 354:40","journal-title":"J. Mol. Biol."},{"key":"335_CR96","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1021\/bi036022q","volume":"43","author":"C Huang","year":"2004","unstructured":"Huang C, Wei P, Fan K, Liu Y, Lai L (2004) 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry 43:4568\u20134574","journal-title":"Biochemistry"},{"key":"335_CR97","first-page":"1742","volume":"3","author":"H Yang","year":"2005","unstructured":"Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Qi Z, Zhou Z, Pei D, Ziebuhr J, Hilgenfeld R, Ky Y, Wong L, Gao G, Chen S, Chen Z, Ma D, Bartlam M, Rao Z (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3:1742\u20131752","journal-title":"PLoS Biol."},{"key":"335_CR98","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","volume":"63","author":"LL Zhang","year":"2020","unstructured":"Zhang LL, Lin DZ, Kusov YR, Nian Y, Ma QJ, Wang J, von Brunn A, Leyssen P, Lanko K, Neyts J, de Wilde A, Snijder EJ, Liu H, Hilgenfeld R (2020) \u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem 63:4562\u20134578","journal-title":"J Med Chem"},{"key":"335_CR99","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"WH Dai","year":"2020","unstructured":"Dai WH, Zhang B, Su HX, Li J, Zhao Y, Xie X, Jin ZM, Liu FJ, Li CP, Li Y, Bai F, Wang HF, Cheng X, Cen XB, Hu SL, Yang XN, Wang J, Liu X, Xiao GF, Jiang HL, Rao ZH, Zhang LK, Xu YC, Yang HT, Liu H (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368:1331\u20131335","journal-title":"Science"},{"key":"335_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"L Fu","year":"2020","unstructured":"Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P, Song H, Shi Y, Li X, Tan W, Qi J, Gao GF (2020) Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11:1","journal-title":"Nat Commun"},{"key":"335_CR101","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","volume":"27","author":"Z Jin","year":"2020","unstructured":"Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Zhu Y, Zhu C, Hu T, Du X, Duan Y, Yu J, Yang X, Yang X, Yang K, Liu X, Guddat LW, Xiao G, Zhang L, Yang H, Rao Z (2020) Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 27:529\u2013532","journal-title":"Nat Struct Mol Biol"},{"key":"335_CR102","first-page":"183","volume":"41","author":"AK Ghosh","year":"2006","unstructured":"Ghosh AK, Xi K, Johnson ME, Baker SC, Mesecar AD (2006) Progress in anti-SARS coronavirus chemistry, biology and chemotherapy. Annu Rep Med Chem 41:183\u2013196","journal-title":"Annu Rep Med Chem"},{"key":"335_CR103","doi-asserted-by":"publisher","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","volume":"96","author":"DA Matthews","year":"1999","unstructured":"Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST (1999) Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 96:11000\u201311007","journal-title":"Proc Natl Acad Sci USA"},{"key":"335_CR104","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1016\/j.bmcl.2003.08.066","volume":"13","author":"E Jenwitheesuk","year":"2003","unstructured":"Jenwitheesuk E, Samudrala R (2003) Identifying inhibitors of the SARS coronavirus proteinase. Bioorg Med Chem Lett 13:3989\u20133992","journal-title":"Bioorg Med Chem Lett"},{"key":"335_CR105","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1021\/jm050548m","volume":"48","author":"AK Ghosh","year":"2005","unstructured":"Ghosh AK, Xi K, Ratia K, Santarsiero BD, Fu WT, Harcourt BH, Rota PA, Baker SC, Johnson ME, Mesecar AD (2005) Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J Med Chem 48:6767\u20136771","journal-title":"J Med Chem"},{"key":"335_CR106","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1016\/j.bmc.2008.01.011","volume":"16","author":"P Mukherjee","year":"2008","unstructured":"Mukherjee P, Desai P, Ross L, White EL, Avery MA (2008) Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits. Biorg Med Chem 16:4138\u20134149","journal-title":"Biorg Med Chem"},{"key":"335_CR107","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1021\/jm0603926","volume":"49","author":"S Yang","year":"2006","unstructured":"Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CTK, Liu YF, Chen HC, Kuo CW, Wu CS, Chang LW, Chen WC, Liao SY, Chang TY, Hung HH, Shr HL, Liu CY, Huang YA, Chang LY, Hsu JC, Peters CJ, Wang AHJ, Hsu MC (2006) Synthesis, crystal structure, structure\u2212activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem 49:4971\u20134980","journal-title":"J Med Chem"},{"key":"335_CR108","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1021\/jm0507678","volume":"49","author":"HZ Zhang","year":"2006","unstructured":"Zhang HZ, Zhang H, Kemnitzer W, Tseng B, Cinatl J, Michaelis M, Doerr HW, Cai SX (2006) Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J Med Chem 49:1198\u20131201","journal-title":"J Med Chem"},{"key":"335_CR109","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.bmcl.2009.03.118","volume":"19","author":"T Regnier","year":"2009","unstructured":"Regnier T, Sarma D, Hidaka K, Bacha U, Freire E, Hayashi Y, Kiso Y (2009) New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett 19:2722\u20132727","journal-title":"Bioorg Med Chem Lett"},{"key":"335_CR110","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.bmc.2012.11.017","volume":"21","author":"S Konno","year":"2013","unstructured":"Konno S, Thanigaimalai P, Yamamoto T, Nakada K, Kakiuchi R, Takayama K, Yamazaki Y, Yakushiji F, Akaji K, Kiso Y, Kawasaki Y, Chen SE, Freire E, Hayashi Y (2013) Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety. Biorg Med Chem 21:412\u2013424","journal-title":"Biorg Med Chem"},{"key":"335_CR111","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejmech.2013.07.037","volume":"68","author":"P Thanigaimalai","year":"2013","unstructured":"Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Chen SE, Naser-Tavakolian A, Sch\u00f6n A, Freire E, Hayashi Y (2013) Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. Eur J Med Chem 68:372\u2013384","journal-title":"Eur J Med Chem"},{"key":"335_CR112","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ejmech.2013.05.005","volume":"65","author":"P Thanigaimalai","year":"2013","unstructured":"Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Kiso Y, Kawasaki Y, Chen SE, Naser-Tavakolian A, Sch\u00f6n A, Freire E, Hayashi Y (2013) Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure\u2013activity relationship study. Eur J Med Chem 65:436\u2013447","journal-title":"Eur J Med Chem"},{"key":"335_CR113","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1021\/jo0157831","volume":"67","author":"YK Ramtohul","year":"2002","unstructured":"Ramtohul YK, James MNG, Vederas JC (2002) Synthesis and evaluation of keto-glutamine analogues as inhibitors of hepatitis A virus 3C proteinase. J Org Chem 67:3169\u20133178","journal-title":"J Org Chem"},{"key":"335_CR114","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1016\/j.bmcl.2004.05.021","volume":"14","author":"RP Jain","year":"2004","unstructured":"Jain RP, Vederas JC (2004) Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase. Bioorg Med Chem Lett 14:3655\u20133658","journal-title":"Bioorg Med Chem Lett"},{"key":"335_CR115","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1021\/jm0494873","volume":"47","author":"RP Jain","year":"2004","unstructured":"Jain RP, Pettersson HI, Zhang J, Aull KD, Fortin PD, Huitema C, Eltis LD, Parrish JC, James MNG, Wishart DS, Vederas JC (2004) Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem 47:6113\u20136116","journal-title":"J Med Chem"},{"key":"335_CR116","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1021\/jm025581c","volume":"45","author":"JL Asgian","year":"2002","unstructured":"Asgian JL, James KE, Li ZZ, Carter W, Barrett AJ, Mikolajczyk J, Salvesen GS, Powers JC (2002) Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J Med Chem 45:4958\u20134960","journal-title":"J Med Chem"},{"key":"335_CR117","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jmb.2005.09.004","volume":"353","author":"TW Lee","year":"2005","unstructured":"Lee TW, Cherney MM, Huitema C, Liu J, James KE, Powers JC, Eltis LD, James MNG (2005) Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J Mol Biol 353:1137\u20131151","journal-title":"J Mol Biol"},{"key":"335_CR118","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/cbic.200700254","volume":"8","author":"YM Shao","year":"2007","unstructured":"Shao YM, Yang WB, Peng HP, Hsu MF, Tsai KC, Kuo TH, Wang AHJ, Liang PH, Lin CH, Yang A-S, Wong CH (2007) Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors. ChemBioChem 8:1654\u20131657","journal-title":"ChemBioChem"},{"key":"335_CR119","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1073\/pnas.95.3.939","volume":"95","author":"T Lee","year":"1998","unstructured":"Lee T, Laco GS, Torbett BE, Fox HS, Lerner DL, Elder JH, Wong CH (1998) Analysis of the S3 and S3\u2019 subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV and HIV in vitro and ex vivo. Proc Natl Acad Sci U S A 95:939\u2013944","journal-title":"Proc Natl Acad Sci U S A"},{"key":"335_CR120","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1021\/jm050184y","volume":"48","author":"JJ Shie","year":"2005","unstructured":"Shie JJ, Fang JM, Kuo CJ, Kuo TH, Liang PH, Huang HJ, Yang WB, Lin CH, Chen JL, Wu YT, Wong CH (2005) Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem 48:4469\u20134473","journal-title":"J Med Chem"},{"key":"335_CR121","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/383272a0","volume":"383","author":"L Tong","year":"1996","unstructured":"Tong L, Qian C, Massariol MJ, Bonneau PR, Cordingley MG, Lagace L (1996) A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 383:272\u2013275","journal-title":"Nature"},{"key":"335_CR122","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0960-894X(00)00462-5","volume":"10","author":"D Dhanak","year":"2000","unstructured":"Dhanak D, Burton G, Christmann LT, Darcy MG, Elrod KC, Kaura A, Keenan RM, Link JO, Peishoff CE, Shah DH (2000) Metal mediated protease inhibition: design and synthesis of inhibitors of the human cytomegalovirus (hCMV) protease. Bioorg Med Chem Lett 10:2279\u20132282","journal-title":"Bioorg Med Chem Lett"},{"key":"335_CR123","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0960-894X(01)00457-7","volume":"11","author":"KS Yeung","year":"2001","unstructured":"Yeung KS, Meanwell NA, Qiu Z, Hernandez D, Zhang S, McPhee F, Weinheimer S, Clark JM, Janc JW (2001) Structure-activity relationship studies of a bisbenzimidazole-based, Zn2+-dependent inhibitor of HCV NS3 serine protease. Bioorg Med Chem Lett 11:2355\u20132359","journal-title":"Bioorg Med Chem Lett"},{"key":"335_CR124","doi-asserted-by":"publisher","first-page":"10349","DOI":"10.1021\/bi0504761","volume":"44","author":"YS Han","year":"2005","unstructured":"Han YS, Chang GG, Juo CG, Lee HJ, Yeh SH, Hsu JTA, Chen X (2005) Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry 44:10349\u201310359","journal-title":"Biochemistry"},{"key":"335_CR125","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.febslet.2004.08.015","volume":"574","author":"JTA Hsu","year":"2004","unstructured":"Hsu JTA, Kuo CJ, Hsieh HP, Wang YC, Huang KK, Lin CPC, Huang PF, Chen X, Liang PH (2004) Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett 574:116\u2013120","journal-title":"FEBS Lett"},{"key":"335_CR126","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1016\/j.febslet.2007.10.048","volume":"581","author":"CC Lee","year":"2007","unstructured":"Lee CC, Kuo CJ, Hsu MF, Liang PH, Fang JM, Shie JJ, Wang AHJ (2007) Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. FEBS Lett 581:5454\u20135458","journal-title":"FEBS Lett"},{"key":"335_CR127","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1021\/bi0361766","volume":"43","author":"U Bacha","year":"2004","unstructured":"Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E (2004) Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43:4906\u20134912","journal-title":"Biochemistry"},{"key":"335_CR128","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1021\/cr608202m","volume":"112","author":"R Smoum","year":"2012","unstructured":"Smoum R, Rubinstein A, Dembitsky VM, Srebnik M (2012) Boron containing compounds as protease inhibitors. Chem Rev 112:4156\u20134220","journal-title":"Chem Rev"},{"key":"335_CR129","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1039\/c004247a","volume":"8","author":"K Knott","year":"2010","unstructured":"Knott K, Fishovitz J, Thorpe SB, Lee I, Santos WL (2010) N-Terminal peptidic boronic acids selectively inhibit human ClpXP. Org Biomol Chem 8:3451\u20133456","journal-title":"Org Biomol Chem"},{"key":"335_CR130","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0946-672X(98)80014-X","volume":"12","author":"M Benderdour","year":"1998","unstructured":"Benderdour M, Bui-Van T, Dicko A, Belleville F (1998) In vivo and in vitro effects of boron and boronated compounds. J Trace Elem Med Biol 12:2\u20137","journal-title":"J Trace Elem Med Biol"},{"key":"335_CR131","doi-asserted-by":"publisher","first-page":"112711","DOI":"10.1016\/j.ejmech.2020.112711","volume":"206","author":"Y Liu","year":"2020","unstructured":"Liu Y, Liang C, Xin L, Ren X, Tian L, Ju X, Li H, Wang Y, Zhao Q, Liu H, Cao W, Xie X, Zhang D, Wang Y, Jian Y (2020) The development of coronavirus 3C-like protease (3CLpro) inhibitors from 2010 to 2020. Eur J Med Chem 206:112711","journal-title":"Eur J Med Chem"},{"key":"335_CR132","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.bmc.2014.12.028","volume":"23","author":"Y Shimamoto","year":"2015","unstructured":"Shimamoto Y, Hattori Y, Kobayashi K, Teruya K, Sanjoh A, Nakagawa A, Yamashita E, Akaji K (2015) Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors. Bioorg Med Chem 23:876\u2013890","journal-title":"Bioorg Med Chem"},{"key":"335_CR133","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"J Jacobs","year":"2013","unstructured":"Jacobs J, Grum-Tokars V, Zhou Y, Turlington M, Saldanha SA, Chase P, Eggler A, Dawson ES, Baez-Santos YM, Tomar S, Mielech AM, Baker SC, Lindsley CW, Hodder P, Mesecar A, Stauffer SR (2013) Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J Med Chem 56:534\u2013546","journal-title":"J Med Chem"},{"key":"335_CR134","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1016\/j.bmcl.2013.08.112","volume":"23","author":"M Turlington","year":"2013","unstructured":"Turlington M, Chun A, Tomar S, Eggler A, Grum-Tokars V, Jacobs J, Daniels JS, Dawson E, Saldanha A, Chase P, Baez-Santos YM, Lindsley CW, Hodder P, Mesecar AD, Stauffer SR (2013) Discovery of N-(benzo 1,2,3 triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorg Med Chem Lett 23:6172\u20136177","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Topics in Current Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41061-021-00335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41061-021-00335-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41061-021-00335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T05:31:18Z","timestamp":1671946278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41061-021-00335-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1007\/s41061-021-00335-9","relation":{},"ISSN":["2365-0869","2364-8961"],"issn-type":[{"type":"print","value":"2365-0869"},{"type":"electronic","value":"2364-8961"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"23"}}